Inhaled PRS-220 Aims to Treat Both IPF and ‘Long Covid’ PF

Inhaled PRS-220 Aims to Treat Both IPF and ‘Long Covid’ PF

297965

Inhaled PRS-220 Aims to Treat Both IPF and ‘Long Covid’ PF

Pieris Pharmaceuticals plans to start clinical development of PRS-220 in 2022 for idiopathic pulmonary fibrosis (IPF) — and also will advance the investigative, inhaled therapy for “long COVID” PF, or post-COVID-19 pulmonary fibrosis, the company said. The clinical development of PRS-220 for long COVID pulmonary fibrosis will be supported by grant of more than €14 million (nearly $17 million) from Germany’s Bavarian Ministry of Economic Affairs, Regional Development and Energy. “This grant for PRS-220 … will…

You must be logged in to read/download the full post.